All In Biotech

Drug Trial Radar · NCT05356741

To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of VIR-5818 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

645

Planned (sponsor's estimate)

Start

Apr 13, 2022

Primary completion

Apr 2028

Study completion Apr 2028

Sponsor

Lead sponsor
Vir Biotechnology, Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
May 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This first-in-human (FIH) Phase 1 open-label multicenter dose-escalation and dose-expansion study is designed to evaluate the safety, pharmacokinetics, and preliminary activity of VIR-5818 (Formerly AMX-818) as a single agent and in combination with pembrolizumab in participants with HER2+ tumors across multiple tumor types. The study will be conducted in four parts: * Part 1 (dose escalation): Single-agent VIR-5818 * Part 2 (dose escalation): VIR-5818 plus pembrolizumab * Part 3 (dose expansion): Single-agent VIR-5818 * Part 4 (dose expansion): VIR-5818 plus pembrolizumab The total length of the study, from screening of the first participant to the end of the study, is expected to be approximately 72 months.

Conditions

  • Locally Advanced or Metastatic HER2-Expressing Cancers

Interventions

  • VIR-5818Drug

    Administered as IV infusion

  • pembrolizumabDrug

    Administered as IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicity - Part 1 and Part 2Time frame: Up to approximately 21 days (Part 1) and 42 days (Part 2)
  2. Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)- Parts 1, 2, 3, and 4Time frame: Up to approximately 55 months
  3. Objective Response Rate (ORR) - Part 3 and Part 4Time frame: Up to approximately 55 months
  4. Duration of Response (DOR) - Part 3 and Part 4Time frame: Up to approximately 55 months

Locations

13 sites in 5 countries. Site status is shown where the registry gives one.

  • Investigational site number #450

    Duarte, California · Recruiting

  • Investigational site number #451

    Palo Alto, California · Recruiting

  • Investigational site number #101

    Randwick, Australia · Recruiting

  • Investigational site number #100

    Melbourne, Victoria, Australia · Active not recruiting

  • Investigational site number #150

    Toulouse, France · Recruiting

  • Investigational site number #200

    Porto, Portugal · Recruiting

  • Investigational site number #255

    Barcelona, Spain · Recruiting

  • Investigational site number #251

    Barcelona, Spain · Recruiting

  • Investigational site number #254

    Madrid, Spain · Recruiting

  • Investigational site number #257

    Madrid, Spain · Recruiting

  • Investigational site number #252

    Madrid, Spain · Recruiting

  • Investigational site number #250

    Pamplona, Spain · Recruiting

  • Investigational site number #253

    Pozuelo de Alarcón, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.